EP3302561A4 - Kombinationen aus anti-cd37-immunkonjugat und anti-cd20-antikörper - Google Patents

Kombinationen aus anti-cd37-immunkonjugat und anti-cd20-antikörper Download PDF

Info

Publication number: EP3302561A4
Authority: EP; European Patent Office
Prior art keywords: immunoconjugates; antibodies; combinations
Prior art date: 2015-06-08
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Withdrawn

Application number

EP16808055.4A

Other languages

English (en)

French (fr)

Other versions

EP3302561A1 (de

Inventor

Angela Romanelli

Rodrigo R. RUIZ-SOTO

Jose Ponte

Jutta Deckert

Jan PINKAS

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Debiopharm International SA

Original Assignee

Debiopharm International SA

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2015-06-08

Filing date

2016-06-02

Publication date

2019-02-06

2016-06-02 Application filed by Debiopharm International SA filed Critical Debiopharm International SA

2018-04-11 Publication of EP3302561A1 publication Critical patent/EP3302561A1/de

2019-02-06 Publication of EP3302561A4 publication Critical patent/EP3302561A4/de

Status Withdrawn legal-status Critical Current

Links

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
- A61K47/68033—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a maytansine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
- A61K47/6867—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell the tumour determinant being from a cell of a blood cancer
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2887—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2896—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- A61K2039/507—Comprising a combination of two or more separate antibodies
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Immunology (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Veterinary Medicine (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Organic Chemistry (AREA)
Epidemiology (AREA)
Cell Biology (AREA)
Genetics & Genomics (AREA)
Biochemistry (AREA)
Biophysics (AREA)
Molecular Biology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Oncology (AREA)
Hematology (AREA)
Dermatology (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Peptides Or Proteins (AREA)
Medicinal Preparation (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Preparation Of Compounds By Using Micro-Organisms (AREA)
Micro-Organisms Or Cultivation Processes Thereof (AREA)
Steroid Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Endocrinology (AREA)
Microbiology (AREA)
Mycology (AREA)

EP16808055.4A 2015-06-08 2016-06-02 Kombinationen aus anti-cd37-immunkonjugat und anti-cd20-antikörper Withdrawn EP3302561A4 (de)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US201562172672P	2015-06-08	2015-06-08
US201562263449P	2015-12-04	2015-12-04
PCT/US2016/035558 WO2016200676A1 (en)	2015-06-08	2016-06-02	Anti-cd37 immunoconjugate and anti-cd20 antibody combinations

Publications (2)

Publication Number	Publication Date
EP3302561A1 EP3302561A1 (de)	2018-04-11
EP3302561A4 true EP3302561A4 (de)	2019-02-06

Family

ID=57504922

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
EP16808055.4A Withdrawn EP3302561A4 (de)	2015-06-08	2016-06-02	Kombinationen aus anti-cd37-immunkonjugat und anti-cd20-antikörper

Country Status (15)

Country	Link
US (3)	US20170000900A1 (de)
EP (1)	EP3302561A4 (de)
JP (2)	JP6979877B2 (de)
KR (1)	KR20180011315A (de)
CN (1)	CN108472361B (de)
AU (1)	AU2016276158B2 (de)
BR (1)	BR112017026027A2 (de)
CA (1)	CA2986437A1 (de)
EA (1)	EA201792300A1 (de)
IL (1)	IL255532B2 (de)
MA (1)	MA44391A (de)
MX (1)	MX392539B (de)
SG (1)	SG10202108116SA (de)
UA (1)	UA125496C2 (de)
WO (1)	WO2016200676A1 (de)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
MX338932B (es)	2010-03-12	2016-05-06	Immunogen Inc	Moleculas de union cd37 y sus inmunoconjugados.
CN105999293B (zh)	2011-04-01	2019-07-23	德彪发姆国际有限公司	Cd37结合分子及其免疫缀合物
UA125496C2 (uk)	2015-06-08	2022-04-13	Дебіофарм Інтернаціонал, С.А.	Спосіб лікування пацієнта з в-клітинним раком імунокон’югатом, який зв’язується з cd37 разом з антитілом, що зв'язується з cd20
AU2016316758B2 (en)	2015-08-28	2023-02-02	Debiopharm International, S.A.	Antibodies and assays for detection of CD37
WO2018083633A1 (en)	2016-11-02	2018-05-11	Debiopharm International, S.A.	Methods for improving anti-cd37 immunoconjugate therapy
WO2018132506A1 (en)	2017-01-10	2018-07-19	The General Hospital Corporation	Chimeric antigen receptors based on alternative signal 1 domains
GB201703876D0 (en) *	2017-03-10	2017-04-26	Berlin-Chemie Ag	Pharmaceutical combinations
EP3595721B1 (de) *	2017-03-16	2025-07-09	The General Hospital Corporation	Chimäre antigenrezeptoren zum targeting von cd37
CN108728465A (zh) *	2017-04-14	2018-11-02	深圳新诺微环生物科技有限公司	一种表达靶细胞-效应细胞桥接器的微环dna载体及其制备方法和应用
EP3658172A4 (de)	2017-07-25	2021-05-05	TrueBinding, Inc.	Behandlung von krebs durch blockierung der interaktion von tim-3 und seinem liganden
CN119798437A (zh) *	2017-08-08	2025-04-11	豪夫迈·罗氏有限公司	一种dlbcl患者亚组的奥滨尤妥珠单抗治疗
EP3713607A1 (de) *	2017-11-22	2020-09-30	Nordic Nanovector ASA	Radioimmunkonjugate in kombination mit anderen arzneimitteln als behandlung gegen nhl
CA3101790A1 (en)	2018-05-30	2019-12-05	Debiopharm International, S.A.	Anti-cd37 immunoconjugate dosing regimens
CN113711036B (zh)	2019-01-30	2025-03-18	真和制药有限公司	抗gal3抗体及其用途
CN116157151A (zh)	2020-05-26	2023-05-23	真和制药有限公司	通过阻断半乳凝素-3治疗炎性疾病的方法
JP2024500847A (ja)	2020-12-18	2024-01-10	センチュリーセラピューティクス，インコーポレイテッド	適合可能な受容体特異性を有するキメラ抗原受容体システム
KR20250175330A (ko) *	2023-04-19	2025-12-16	다이이찌 산쿄 가부시키가이샤	항체-약물 콘주게이트와 다른 약제의 조합

Citations (6)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO2007014278A2 (en) *	2005-07-25	2007-02-01	Trubion Pharmaceuticals, Inc.	B-cell reduction using cd37-specific and cd20-specific binding molecules
US20080279850A1 (en) *	2005-07-25	2008-11-13	Trubion Pharmaceuticals, Inc.	B-Cell Reduction Using CD37-Specific and CD20-Specific Binding Molecules
WO2011112978A1 (en) *	2010-03-12	2011-09-15	Immunogen, Inc.	Cd37-binding molecules and immunoconjugates thereof
WO2013149171A2 (en) *	2012-03-30	2013-10-03	Immunogen, Inc.	Methods for increasing efficacy of cd37-based therapy
WO2013171289A1 (en) *	2012-05-16	2013-11-21	Boehringer Ingelheim International Gmbh	Combination of cd37 antibodies with further agents
WO2014195460A1 (en) *	2013-06-07	2014-12-11	Nordic Nanovector As	Method for upregulating antigen expression

Family Cites Families (76)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4563304A (en)	1981-02-27	1986-01-07	Pharmacia Fine Chemicals Ab	Pyridine compounds modifying proteins, polypeptides or polysaccharides
US5225539A (en)	1986-03-27	1993-07-06	Medical Research Council	Recombinant altered antibodies and methods of making altered antibodies
FI102355B1 (fi)	1988-02-11	1998-11-30	Bristol Myers Squibb Co	Menetelmä yhdistävän välikappaleen omaavien antrasykliini-immunokonjugaattien valmistamiseksi
US5595756A (en)	1993-12-22	1997-01-21	Inex Pharmaceuticals Corporation	Liposomal compositions for enhanced retention of bioactive agents
US5977316A (en)	1995-01-17	1999-11-02	The Board Of Trustees Of The University Of Kentucky	Monoclonal antibody 1A7 and related polypeptides
US7303749B1 (en)	1999-10-01	2007-12-04	Immunogen Inc.	Compositions and methods for treating cancer using immunoconjugates and chemotherapeutic agents
CA2385528C (en)	1999-10-01	2013-12-10	Immunogen, Inc.	Compositions and methods for treating cancer using immunoconjugates and chemotherapeutic agents
KR20030031957A (ko)	2000-07-12	2003-04-23	아이덱 파마슈티칼즈 코포레이션	Ｂ 세포 고갈 항체 및 면역 조절 항체 관련 적용의 조합을이용한 ｂ 세포 악성종양의 치료
US6333410B1 (en)	2000-08-18	2001-12-25	Immunogen, Inc.	Process for the preparation and purification of thiol-containing maytansinoids
US7754208B2 (en)	2001-01-17	2010-07-13	Trubion Pharmaceuticals, Inc.	Binding domain-immunoglobulin fusion proteins
US7829084B2 (en)	2001-01-17	2010-11-09	Trubion Pharmaceuticals, Inc.	Binding constructs and methods for use thereof
CN100574803C (zh)	2001-01-31	2009-12-30	拜奥根Idec公司	免疫调节抗体在治疗肿瘤性疾病中的用途
AU2002237972B2 (en)	2001-01-31	2007-11-29	Biogen Idec Inc.	Use of CD23 antagonists for the treatment of neoplastic disorders
US20030103971A1 (en)	2001-11-09	2003-06-05	Kandasamy Hariharan	Immunoregulatory antibodies and uses thereof
US6441163B1 (en)	2001-05-31	2002-08-27	Immunogen, Inc.	Methods for preparation of cytotoxic conjugates of maytansinoids and cell binding agents
CA2450793A1 (en)	2001-06-20	2002-12-27	Prochon Biotech Ltd.	Antibodies that block receptor protein tyrosine kinase activation, methods of screening for and uses thereof
WO2003040187A1 (en)	2001-11-08	2003-05-15	Yang Sheng Tang Company Limited	Hepatitis e virus monoclonal antibodies or the binding fragments of it and the use thereof
DE60230918D1 (de)	2001-11-16	2009-03-05	Biogen Idec Inc	Polycistronische expression von antikörpern in cho zellen
US6716821B2 (en)	2001-12-21	2004-04-06	Immunogen Inc.	Cytotoxic agents bearing a reactive polyethylene glycol moiety, cytotoxic conjugates comprising polyethylene glycol linking groups, and methods of making and using the same
CA2505717A1 (en)	2002-11-15	2004-06-03	Immunomedics, Inc.	Use of multi-specific, non-covalent complexes for targeted delivery of therapeutics
JP4959136B2 (ja)	2002-12-13	2012-06-20	イミューノメディクス、インコーポレイテッド	細胞内で開裂可能な結合を有する免疫接合体
US7534427B2 (en)	2002-12-31	2009-05-19	Immunomedics, Inc.	Immunotherapy of B cell malignancies and autoimmune diseases using unconjugated antibodies and conjugated antibodies and antibody combinations and fusion proteins
KR101351122B1 (ko)	2003-05-09	2014-01-14	듀크 유니버시티	Ｃｄ２０-특이적 항체 및 이를 이용한 방법
US8088387B2 (en)	2003-10-10	2012-01-03	Immunogen Inc.	Method of targeting specific cell populations using cell-binding agent maytansinoid conjugates linked via a non-cleavable linker, said conjugates, and methods of making said conjugates
US7276497B2 (en)	2003-05-20	2007-10-02	Immunogen Inc.	Cytotoxic agents comprising new maytansinoids
US7754209B2 (en)	2003-07-26	2010-07-13	Trubion Pharmaceuticals	Binding constructs and methods for use thereof
US7241598B2 (en)	2004-06-29	2007-07-10	The Chinese University Of Hong Kong	Frame-shifting PCR for germline immunoglobulin genes retrieval and antibody engineering
US7371825B2 (en)	2004-06-30	2008-05-13	Centocor, Inc.	Anti-MCP-1 antibodies, compositions, methods and uses
AU2005279347A1 (en)	2004-08-30	2006-03-09	Lonza Biologics Plc.	Affinity- plus ion exchange- chromatography for purifying antibodies
AU2006203889A1 (en)	2005-01-05	2006-07-13	Biogen Idec Ma Inc.	CRIPTO binding molecules
JP5837730B2 (ja)	2005-02-10	2015-12-24	ベイラーリサーチインスティテュートＢａｙｌｏｒＲｅｓｅａｒｃｈＩｎｓｔｉｔｕｔｅ	抗インターフェロンアルファモノクローナル抗体及び使用方法
US8318906B2 (en)	2005-04-15	2012-11-27	The Regents Of The University Of California	EMP2 antibodies and their therapeutic uses
WO2006117910A1 (ja)	2005-04-28	2006-11-09	Mochida Pharmaceutical Co., Ltd.	抗血小板膜糖蛋白質ⅵモノクローナル抗体
ZA200709956B (en)	2005-05-20	2009-02-25	Genentech Inc	Pretreatment of a biological sample from an autoimmune disease subject
WO2006133450A2 (en)	2005-06-08	2006-12-14	Duke University	Anti-cd19 antibody therapy for the transplantation
EP1806365A1 (de)	2006-01-05	2007-07-11	Boehringer Ingelheim International GmbH	Antikörper spezifisch für Fibroblasten-Aktivierungsprotein und Immunokonjugaten, die diese Antikörper enthalten
WO2007140371A2 (en)	2006-05-30	2007-12-06	Genentech, Inc.	Antibodies and immunoconjugates and uses therefor
CN105837690A (zh)	2006-06-12	2016-08-10	新兴产品开发西雅图有限公司	具有效应功能的单链多价结合蛋白
AU2007282023B2 (en)	2006-08-03	2012-09-13	Vaccinex, Inc.	Anti-IL-6 monoclonal antibodies and uses thereof
US7846434B2 (en)	2006-10-24	2010-12-07	Trubion Pharmaceuticals, Inc.	Materials and methods for improved immunoglycoproteins
CA2663536A1 (en)	2006-10-24	2008-05-02	Trubion Pharmaceuticals, Inc.	Materials and methods for improved immunoglycoproteins
US7691980B2 (en)	2007-01-09	2010-04-06	Bio-Rad Laboratories, Inc.	Enhanced capacity and purification of antibodies by mixed mode chromatography in the presence of aqueous-soluble nonionic organic polymers
SG10201808730VA (en)	2007-04-03	2018-11-29	Amgen Res Munich Gmbh	Cross-species-specific binding domain
CN101990439A (zh)	2007-07-06	2011-03-23	特鲁比昂药品公司	具有置于c末端的特异性结合结构域的结合肽
PE20140196A1 (es)	2007-08-09	2014-03-19	Boehringer Ingelheim Int	Anticuerpos anti-cd37
GB2454915B (en)	2007-11-23	2012-02-15	Schlumberger Holdings	Spooling apparatus for well intervention system
WO2009085576A2 (en)	2007-12-28	2009-07-09	Spring Bioscience Corporation	Positive control cell pellets for immunohistochemistry and methods of use thereof
US8093364B2 (en)	2008-01-18	2012-01-10	Bio-Rad Laboratories, Inc.	Enhanced purification of antibodies and antibody fragments by apatite chromatography
PT2132228E (pt)	2008-04-11	2011-10-11	Emergent Product Dev Seattle	Imunoterapia de cd37 e sua combinação com um quimioterápico bifuncional
US7740844B2 (en)	2008-04-29	2010-06-22	Taiwan Liposome Co. Ltd	Anti-VEGF monoclonal antibody
EP2281006B1 (de)	2008-04-30	2017-08-02	Immunogen, Inc.	Vernetzer und ihre verwendung
JP2011524421A (ja)	2008-06-16	2011-09-01	イミュノジェン・インコーポレーテッド	新規の相乗効果
WO2010009124A2 (en)	2008-07-15	2010-01-21	Genentech, Inc.	Anthracycline derivative conjugates, process for their preparation and their use as antitumor compounds
WO2010057047A1 (en)	2008-11-13	2010-05-20	Trubion Pharmaceutics, Inc.	Cd37 immunotherapeutic combination therapies and uses thereof
JP2013506709A (ja)	2009-10-06	2013-02-28	イミュノジェン・インコーポレーテッド	有効なコンジュゲートおよび親水性リンカー
SI2519543T1 (sl)	2009-12-29	2016-08-31	Emergent Product Development Seattle, Llc	Beljakovine, ki se vežejo s heterodimeri in njihova uporaba
AR080155A1 (es)	2010-02-10	2012-03-14	Immunogen Inc	Anticuerpos anti-cd20 y su utilizacion
US9173961B2 (en)	2010-02-10	2015-11-03	Immunogen, Inc.	CD20 antibodies and uses thereof
AU2011239583A1 (en)	2010-04-15	2012-11-29	Alper Biotech, Llc	Monoclonal antibodies against HER2 antigens, and uses therefor
TR201902180T4 (tr)	2011-03-29	2019-03-21	Immunogen Inc	Tek adimli bi̇r i̇şlem i̇le maytansi̇noi̇d anti̇kor konjugatlarinin hazirlanmasi
CN105999293B (zh)	2011-04-01	2019-07-23	德彪发姆国际有限公司	Cd37结合分子及其免疫缀合物
US20120282282A1 (en)	2011-04-04	2012-11-08	Immunogen, Inc.	Methods for Decreasing Ocular Toxicity of Antibody Drug Conjugates
US20130058947A1 (en)	2011-09-02	2013-03-07	Stem Centrx, Inc	Novel Modulators and Methods of Use
KR20140103140A (ko)	2011-12-13	2014-08-25	노르딕 나노벡터 에이에스	치료용 키메릭 항-cd37 항체 hh1
US20140120083A1 (en) *	2012-11-01	2014-05-01	Infinity Pharmaceuticals, Inc.	Treatment of cancers using pi3 kinase isoform modulators
AU2013360335B2 (en)	2012-12-13	2017-12-07	Immunomedics, Inc.	Dosages of immunoconjugates of antibodies and SN-38 for improved efficacy and decreased toxicity
WO2014143807A2 (en) *	2013-03-15	2014-09-18	Stromatt Scott	Anti-cd37 antibody and bcr pathway antagonist combination therapy for treatment of b-cell malignancies and disorders
US20160130659A1 (en)	2013-06-05	2016-05-12	Merck Sharp & Dohme Corp.	Compositions and methods for treating cancer
IL312865B2 (en) *	2013-09-11	2025-06-01	Eagle Biologics Inc	Liquid protein formulations containing viscosity-lowering agents
JP6478989B2 (ja) *	2013-11-07	2019-03-06	エフ．ホフマン−ラロシュアーゲーＦ．Ｈｏｆｆｍａｎｎ−ＬａＲｏｃｈｅＡｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ	抗ｃｄ２０抗体とｂｔｋ阻害剤とを用いた併用療法
WO2015116729A2 (en)	2014-01-28	2015-08-06	Emergent Product Development Seattle, Llc	Anti-cd37 antibody and anti-cd20 antibody combination therapy for treatment of b-cell malignancies and disorders
WO2015175533A2 (en)	2014-05-13	2015-11-19	Immunogen, Inc.	Anti-cd37 immunoconjugate dosing regimens
UA125496C2 (uk)	2015-06-08	2022-04-13	Дебіофарм Інтернаціонал, С.А.	Спосіб лікування пацієнта з в-клітинним раком імунокон’югатом, який зв’язується з cd37 разом з антитілом, що зв'язується з cd20
AU2016316758B2 (en)	2015-08-28	2023-02-02	Debiopharm International, S.A.	Antibodies and assays for detection of CD37
WO2018083633A1 (en)	2016-11-02	2018-05-11	Debiopharm International, S.A.	Methods for improving anti-cd37 immunoconjugate therapy
CA3101790A1 (en)	2018-05-30	2019-12-05	Debiopharm International, S.A.	Anti-cd37 immunoconjugate dosing regimens

2016
- 2016-06-02 UA UAA201711212A patent/UA125496C2/uk unknown
- 2016-06-02 SG SG10202108116SA patent/SG10202108116SA/en unknown
- 2016-06-02 EP EP16808055.4A patent/EP3302561A4/de not_active Withdrawn
- 2016-06-02 EA EA201792300A patent/EA201792300A1/ru unknown
- 2016-06-02 WO PCT/US2016/035558 patent/WO2016200676A1/en not_active Ceased
- 2016-06-02 MX MX2017015039A patent/MX392539B/es unknown
- 2016-06-02 CN CN201680034479.8A patent/CN108472361B/zh not_active Expired - Fee Related
- 2016-06-02 US US15/171,732 patent/US20170000900A1/en not_active Abandoned
- 2016-06-02 KR KR1020187000183A patent/KR20180011315A/ko not_active Ceased
- 2016-06-02 MA MA044391A patent/MA44391A/fr unknown
- 2016-06-02 AU AU2016276158A patent/AU2016276158B2/en not_active Ceased
- 2016-06-02 CA CA2986437A patent/CA2986437A1/en not_active Abandoned
- 2016-06-02 BR BR112017026027A patent/BR112017026027A2/pt not_active IP Right Cessation
- 2016-06-02 JP JP2017563282A patent/JP6979877B2/ja not_active Expired - Fee Related
2017
- 2017-11-08 IL IL255532A patent/IL255532B2/en unknown
2018
- 2018-10-25 US US16/170,160 patent/US11395796B2/en active Active
2020
- 2020-11-13 JP JP2020189353A patent/JP2021014468A/ja active Pending
2022
- 2022-07-25 US US17/814,728 patent/US12239732B2/en active Active

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO2007014278A2 (en) *	2005-07-25	2007-02-01	Trubion Pharmaceuticals, Inc.	B-cell reduction using cd37-specific and cd20-specific binding molecules
US20080279850A1 (en) *	2005-07-25	2008-11-13	Trubion Pharmaceuticals, Inc.	B-Cell Reduction Using CD37-Specific and CD20-Specific Binding Molecules
WO2011112978A1 (en) *	2010-03-12	2011-09-15	Immunogen, Inc.	Cd37-binding molecules and immunoconjugates thereof
WO2013149171A2 (en) *	2012-03-30	2013-10-03	Immunogen, Inc.	Methods for increasing efficacy of cd37-based therapy
WO2013171289A1 (en) *	2012-05-16	2013-11-21	Boehringer Ingelheim International Gmbh	Combination of cd37 antibodies with further agents
WO2014195460A1 (en) *	2013-06-07	2014-12-11	Nordic Nanovector As	Method for upregulating antigen expression

Non-Patent Citations (11)

* Cited by examiner, † Cited by third party
Title
ALGATE PAUL A ET AL: "TRU-016, An Anti-CD37 SMIP (TM) Biologic, In Combination with Other Therapeutic Drugs In Models of Non-Hodgkin's Lymphoma", BLOOD, vol. 116, no. 21, 1603, November 2010 (2010-11-01), & 52ND ANNUAL MEETING OF THE AMERICAN-SOCIETY-OF-HEMATOLOGY (ASH); ORLANDO, FL, USA; DECEMBER 04 -07, 2010, XP002787336 *
CHEN ROBERT ET AL: "A phase II study of vorinostat and rituximab for treatment of newly diagnosed and relapsed/refractory indolent non-Hodgkin lymphoma.", HAEMATOLOGICA, vol. 100, no. 3, March 2015 (2015-03-01), pages 357 - 362, XP002787338, ISSN: 1592-8721 *
DECKERT JUTTA ET AL: "IMGN529, a Novel Antibody-Drug Conjugate (ADC) Targeting CD37 Shows Synergistic Activity with Rituximab in Non-Hodgkin Lymphoma (NHL) Models", BLOOD, vol. 126, no. 23, December 2015 (2015-12-01), & 57TH ANNUAL MEETING OF THE AMERICAN-SOCIETY-OF-HEMATOLOGY; ORLANDO, FL, USA; DECEMBER 05 -08, 2015, XP002787337 *
GOPAL AJAY K ET AL: "Phase 1b Study of TRU-016, an Anti-CD37 SMIP (TM) Protein, in Combination with Rituximab and Bendamustine in Relapsed Indolent Lymphoma patients (author manuscript)", INVESTIGATIONAL NEW DRUGS, November 2012 (2012-11-01), Presented at ASH Annual Meeting 2012, XP002787335, DOI: 10.1007/s10637-014-0125-2 *
JANE GROSS: "3333: Evaluation of Otlertuzumab (TRU-016), an Anti-CD37 ADAPTIRTM Therapeutic in Preclinical Combination Studies with Kinase Inhibitors and a Next Generation Anti-CD20 Mab in Vitro and in Animal Models of Non-Hodgkin's Lymphoma", vol. 124, no. 21, 6 December 2014 (2014-12-06), pages 3333, XP009506126, ISSN: 0006-4971, Retrieved from the Internet <URL:http://www.bloodjournal.org/content/124/21/3333> [retrieved on 20180618] *
OKI YASUHIRO ET AL: "Pegylated liposomal doxorubicin replacing conventional doxorubicin in standard R-CHOP chemotherapy for elderly patients with diffuse large B-cell lymphoma: an open label, single arm, phase II trial.", CLINICAL LYMPHOMA, MYELOMA & LEUKEMIA, vol. 15, no. 3, March 2015 (2015-03-01), pages 152 - 158, XP002787339, ISSN: 2152-2669 *
PIOTR SMOLEWSKI ET AL: "Pro-apoptotic effect of an anti-CD37 scFv-Fc fusion protein, in combination with the anti-CD20 antibody, ofatumumab, on tumour cells from B-cell malignancies", EUROPEAN JOURNAL OF CANCER, vol. 50, no. 15, 1 October 2014 (2014-10-01), pages 2677 - 2684, XP055157269, ISSN: 0959-8049, DOI: 10.1016/j.ejca.2014.07.021 *
ROBAK TADEUSZ ET AL: "TRU-016, a humanized anti-CD37 IgG fusion protein for the potential treatment of B-cell malignancies", CURRENT OPINION IN INVESTIGATIONAL D, vol. 10, no. 12, 1 December 2009 (2009-12-01), THOMSON REUTERS (SCIENTIFIC) LTD, LONDON, UK, pages 1383 - 1390, XP009172108, ISSN: 2040-3429 *
See also references of WO2016200676A1 *
STATHIS ANASTASIOS ET AL: "Safety, tolerability, and preliminary activity of IMGN529, a CD37-targeted antibody-drug conjugate, in patients with relapsed or refractory B-cell non-Hodgkin lymphoma: a dose-escalation, phase I study", INVESTIGATIONAL NEW DRUGS, MARTINUS NIJHOFF PUBLISHERS, BOSTON, US, vol. 36, no. 5, 17 February 2018 (2018-02-17), pages 869 - 876, XP036590591, ISSN: 0167-6997, [retrieved on 20180217], DOI: 10.1007/S10637-018-0570-4 *
STUART W. HICKS ET AL: "The Antitumor Activity of IMGN529, a CD37-Targeting Antibody-Drug Conjugate, Is Potentiated by Rituximab in Non-Hodgkin Lymphoma Models", NEOPLASIA, vol. 19, no. 9, 1 September 2017 (2017-09-01), US, pages 661 - 671, XP055611917, ISSN: 1476-5586, DOI: 10.1016/j.neo.2017.06.001 *

Also Published As

Publication number	Publication date
JP2021014468A (ja)	2021-02-12
MX2017015039A (es)	2018-08-09
CN108472361A (zh)	2018-08-31
KR20180011315A (ko)	2018-01-31
MA44391A (fr)	2019-01-23
MX392539B (es)	2025-03-24
SG10202108116SA (en)	2021-08-30
US12239732B2 (en)	2025-03-04
AU2016276158A1 (en)	2017-12-14
IL255532B1 (en)	2023-01-01
US20170000900A1 (en)	2017-01-05
UA125496C2 (uk)	2022-04-13
CA2986437A1 (en)	2016-12-15
IL255532A (en)	2018-02-28
JP6979877B2 (ja)	2021-12-15
US11395796B2 (en)	2022-07-26
EP3302561A1 (de)	2018-04-11
US20230190638A1 (en)	2023-06-22
BR112017026027A2 (pt)	2018-08-14
US20190183788A1 (en)	2019-06-20
EA201792300A1 (ru)	2018-09-28
WO2016200676A1 (en)	2016-12-15
JP2018517714A (ja)	2018-07-05
AU2016276158B2 (en)	2022-06-30
IL255532B2 (en)	2023-05-01
CN108472361B (zh)	2022-12-27

Legal Events

Date	Code	Title	Description
2016-12-16	STAA	Information on the status of an ep patent application or granted ep patent	Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE
2018-03-09	PUAI	Public reference made under article 153(3) epc to a published international application that has entered the european phase	Free format text: ORIGINAL CODE: 0009012
2018-03-09	STAA	Information on the status of an ep patent application or granted ep patent	Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE
2018-04-11	17P	Request for examination filed	Effective date: 20171221
2018-04-11	AK	Designated contracting states	Kind code of ref document: A1 Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR
2018-04-11	AX	Request for extension of the european patent	Extension state: BA ME
2019-01-16	RIC1	Information provided on ipc code assigned before grant	Ipc: A61P 35/02 20060101ALI20181213BHEP Ipc: A61K 39/395 20060101AFI20181213BHEP Ipc: A61P 35/00 20060101ALI20181213BHEP Ipc: C07K 16/28 20060101ALI20181213BHEP
2019-01-23	RIC1	Information provided on ipc code assigned before grant	Ipc: A61K 39/395 20060101AFI20181220BHEP Ipc: A61P 35/00 20060101ALI20181220BHEP Ipc: A61P 35/02 20060101ALI20181220BHEP Ipc: C07K 16/28 20060101ALI20181220BHEP
2019-02-06	A4	Supplementary search report drawn up and despatched	Effective date: 20190108
2019-07-05	REG	Reference to a national code	Ref country code: HK Ref legal event code: DE Ref document number: 1253794 Country of ref document: HK
2020-03-24	STAA	Information on the status of an ep patent application or granted ep patent	Free format text: STATUS: EXAMINATION IS IN PROGRESS
2020-04-29	17Q	First examination report despatched	Effective date: 20200327
2023-06-14	P01	Opt-out of the competence of the unified patent court (upc) registered	Effective date: 20230505
2024-06-04	GRAP	Despatch of communication of intention to grant a patent	Free format text: ORIGINAL CODE: EPIDOSNIGR1
2024-06-04	STAA	Information on the status of an ep patent application or granted ep patent	Free format text: STATUS: GRANT OF PATENT IS INTENDED
2024-07-10	INTG	Intention to grant announced	Effective date: 20240605
2025-02-07	STAA	Information on the status of an ep patent application or granted ep patent	Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN
2025-03-12	18D	Application deemed to be withdrawn	Effective date: 20241008
2025-12-24	REG	Reference to a national code	Ref country code: HK Ref legal event code: WD Ref document number: 1253794 Country of ref document: HK

Publication	Publication Date	Title
MA44391A (fr)	2019-01-23	Combinaisons d'immunoconjugués anti-cd37 et d'anticorps anti-cd20
MA46525A (fr)	2019-08-21	Anticorps anti-lag-3 et compositions
MA44659A (fr)	2021-04-14	Anticorps anti-tim-3 et compositions
IL258931A (en)	2018-06-28	Therapeutic compounds and methods
IL259441A (en)	2018-07-31	Materials and methods for treatment of titin-based myopathies and other titinopaties
ZA201801401B (en)	2019-08-28	Anti-dll3 antibody drug conjugates and methods of use
EP3397276A4 (de)	2019-12-18	Antikörper und konjugate davon
MA42950A (fr)	2018-08-01	Administration d'agents de potentialisation de cftr modifiés au deutérium
EP3693391C0 (de)	2024-08-21	Anti-ccl-1-antikörper und immunkonjugate
KR20180084817A (ko)	2018-07-25	항-siglec-9 항체 및 이의 이용 방법
EP3436482A4 (de)	2020-03-11	Antikörper, pharmazeutische zusammensetzungen und verfahren
PT3827845T (pt)	2022-07-08	Formulações subcutâneas de anticorpos anti-cd38 e suas utilizações
MA49715A (fr)	2019-10-09	Oligomères et conjugués d'oligomères
PT3221363T (pt)	2020-07-23	Anticorpos contra cd73 e utilizações dos mesmos
PL4234581T3 (pl)	2026-01-26	Przeciwciała terapeutyczne i ich zastosowania
PL3295951T3 (pl)	2020-10-05	Przeciwciała anty-pvrig i sposoby ich zastosowania
PL3280441T3 (pl)	2022-02-21	Przeciwciała przeciwko sortilinie i sposoby ich stosowania
EP3363816A4 (de)	2019-10-09	Anti-ox40-antikörper und verwendungen davon
EP3554558A4 (de)	2020-10-28	Hsp90-targeting-konjugate und formulierungen davon
EP3386986A4 (de)	2019-07-24	Gold-porphyrin-peg-konjugate und verfahren zur verwendung
EP3310376A4 (de)	2019-01-23	Modifizierte therapeutische mittel und zusammensetzungen daraus
EP3374383A4 (de)	2019-05-15	Amyloid-beta-epitope und antikörper dagegen
IL266132B (en)	2021-12-01	Pharmaceutical formulations and methods for their preparation
EP3373937A4 (de)	2019-05-08	Anti-cd22-antikörper-maytansin-konjugate und verfahren zur verwendung davon
EP3359465A4 (de)	2019-05-08	Polsterstruktur und verpackungsanordnung